FDA Adverse Event Malfunction Summary report: N

OMNIPOD INSULIN PUMP

MDR report key: 2983263 · Received February 1, 2013

Report

Report Number
3004464228-2013-00087
Event Type
Malfunction
Date Received
February 1, 2013
Date of Event
January 4, 2013
Report Date
January 4, 2013
Manufacturer
INSULET CORPORATION
Product Code
LZG
PMA / PMN Number
K042792
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE WAS DISCARDED AND WILL NOT RETURN FOR EVALUATION. WE ARE UNABLE TO CONFIRM THE KINKED CANNULA OR TO DETERMINE IF IT COULD HAVE CONTRIBUTED TO THE REPORTED HYPERGLYCEMIA. NO PRODUCT LOT NUMBER WAS REPORTED THEREFORE NO QUALIFICATION RECORDS COULD BE REVIEWED. THE OMNIPOD USER GUIDE WARNS: "TEST RESULTS GREATER THAN 250 MG/DL MEAN HIGH BLOOD GLUCOSE (HYPERGLYCEMIA). IF YOU GET RESULTS ABOVE 250 MG/DL, BUT DO NOT HAVE SYMPTOMS OF HYPERGLYCEMIA, REPEAT THE TEST. IF YOU HAVE THE SYMPTOMS OR CONTINUE TO GET RESULTS THAT FALL ABOVE 250 MG/DL, FOLLOW THE TREATMENT ADVICE OF YOUR HEALTHCARE PROVIDER." AND ADVISES "IF YOUR BLOOD GLUCOSE IS 250 MG/DL OR ABOVE, CHECK FOR KETONES. IF KETONES ARE NOT PRESENT, TAKE A CORRECTION BOLUS AS PRESCRIBED BY YOUR HEALTHCARE PROVIDER. CHECK BLOOD GLUCOSE AGAIN AFTER 2 HOURS. IF BLOOD GLUCOSE LEVELS HAVE NOT DECREASED, TAKE A SECOND BOLUS BY INJECTION, USING A STERILE SYRINGE. IF BLOOD GLUCOSE REMAINS HIGH AFTER ANOTHER 2 HOURS (A TOTAL OF 4 HOURS), REPLACE THE POD. USE A NEW VIAL OF INSULIN TO FILL THE NEW POD."

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT HIS BLOOD GLUCOSE RANGED FROM 240 - 402 MG/DL WHILE WEARING THE POD. WHEN HE REMOVED IT HE OBSERVED THAT THE CANNULA WAS KINKED AT A 90 DEGREE ANGLE AND THERE WAS BLOOD IN THE CANNULA. AFTER HE ACTIVATED A NEW DEVICE HIS BG BEGAN TO LOWER. THE SUBJECT DEVICE WAS DISCARDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
45281 OMNIPOD INSULIN PUMP PUMP, INFUSION, INSULIN LZG INSULET CORPORATION 11200

Patients

Seq Age Sex Outcome Treatment
1 50 YR